Newly published GARDP-sponsored research offers encouraging evidence for expanding treatment options for newborns with sepsis.
🔗 pubmed.ncbi.nlm.nih.gov/42705380/
#AMR #GARDP
pubmed.ncbi.nlm.nih.gov
In vitro activity of flomoxef, fosfomycin and amikacin versus a global panel of third-generation cephalosporin-resistant Enterobacterales and prediction of their ability in pairwise combinations to work as carbapenem-sparing regimens - PubMed
The results confirm the potential of these combinations as carbapenem-sparing treatments and provide additional evidence to support the evaluation of these combinations in the neonatal sepsis trial that is sponsored by GARDP (ISRCTN48721236).